lactic acid has been researched along with Hyperplasia in 24 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effect of a polymeric-based periadventitial delivery of a nitric oxide (NO)-releasing diazeniumdiolate, spermine/NO (SPER/NO), on balloon injury-induced neointimal hyperplasia in rat ileofemoral arteries." | 3.70 | Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. ( Cercek, B; Dimayuga, P; Fishbein, MC; Kaul, S; Molloy, MD; Nilsson, J; Parikh, AK; Rajavashisth, TB; Rengstrom, J; Shah, PK; Xu, XP, 2000) |
| "Intimal hyperplasia is a major reason for the restenosis of vein grafts." | 1.42 | Inhibition of intimal hyperplasia of the vein graft with degradable poly lactic-co-glycolic acid vascular external sheaths carrying slow-release bosentan. ( Gu, T; Mao, N; Shi, E; Xie, P; Zhang, Y, 2015) |
| "Intimal hyperplasia was assessed in iliac arteries 4 weeks after angioplasty." | 1.30 | Intramural injection of biodegradable microspheres as a local drug-delivery system to inhibit neointimal thickening in a rabbit model of balloon angioplasty. ( Bauters, C; Bertrand, M; Flautre, B; Fournier, C; Gosselin, B; Hamon, M; Lablanche, JM; Meurice, T; Valéro, F; Van Belle, E, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Bellosta, S | 1 |
| Selmin, F | 1 |
| Magri, G | 1 |
| Castiglioni, S | 1 |
| Procacci, P | 1 |
| Sartori, P | 1 |
| Scarpa, E | 1 |
| Tolva, V | 1 |
| Rossi, C | 1 |
| Puoci, F | 1 |
| Rizzello, L | 1 |
| Cilurzo, F | 1 |
| Mylonaki, I | 2 |
| Trosi, O | 1 |
| Allémann, E | 2 |
| Durand, M | 1 |
| Jordan, O | 2 |
| Delie, F | 2 |
| Patel, B | 1 |
| Gupta, N | 1 |
| Ahsan, F | 1 |
| Brahmbhatt, A | 1 |
| NievesTorres, E | 1 |
| Yang, B | 1 |
| Edwards, WD | 1 |
| Roy Chaudhury, P | 1 |
| Lee, MK | 1 |
| Kong, H | 1 |
| Mukhopadhyay, D | 1 |
| Kumar, R | 1 |
| Misra, S | 1 |
| Lee, CH | 1 |
| Yu, CY | 1 |
| Chang, SH | 1 |
| Hung, KC | 1 |
| Liu, SJ | 1 |
| Wang, CJ | 1 |
| Hsu, MY | 1 |
| Hsieh, IC | 1 |
| Chen, WJ | 1 |
| Ko, YS | 1 |
| Wen, MS | 1 |
| Xie, P | 1 |
| Shi, E | 1 |
| Gu, T | 1 |
| Zhang, Y | 1 |
| Mao, N | 1 |
| Wu, B | 1 |
| Mottola, G | 1 |
| Chatterjee, A | 1 |
| Lance, KD | 1 |
| Chen, M | 1 |
| Siguenza, IO | 1 |
| Desai, TA | 1 |
| Conte, MS | 1 |
| Strano, F | 1 |
| Deglise, S | 1 |
| Alonso, F | 1 |
| Corpataux, JM | 1 |
| Dubuis, C | 1 |
| Haefliger, JA | 1 |
| Saucy, F | 1 |
| Park, K | 1 |
| Yang, J | 2 |
| Zeng, Y | 2 |
| Li, Y | 1 |
| Song, C | 2 |
| Zhu, W | 2 |
| Guan, H | 1 |
| Li, X | 1 |
| Kanjickal, D | 1 |
| Lopina, S | 1 |
| Evancho-Chapman, MM | 1 |
| Schmidt, S | 1 |
| Donovan, D | 1 |
| Qiu, XF | 1 |
| Dong, NG | 1 |
| Sun, ZQ | 1 |
| Hu, P | 1 |
| Su, W | 1 |
| Shi, JW | 1 |
| Zou, J | 1 |
| Zhang, X | 1 |
| Yang, H | 1 |
| Zhu, Y | 1 |
| Ma, H | 1 |
| Wang, S | 1 |
| Li, H | 1 |
| Zhong, H | 1 |
| Xu, K | 1 |
| Yang, K | 1 |
| Liu, J | 1 |
| Zhang, B | 1 |
| Zheng, F | 1 |
| Xia, Y | 1 |
| Tan, L | 1 |
| Hong, D | 1 |
| Yue, M | 1 |
| Grube, E | 1 |
| Sonoda, S | 1 |
| Ikeno, F | 1 |
| Honda, Y | 1 |
| Kar, S | 1 |
| Chan, C | 1 |
| Gerckens, U | 1 |
| Lansky, AJ | 1 |
| Fitzgerald, PJ | 1 |
| Meng, B | 1 |
| Wang, J | 1 |
| Zhu, N | 1 |
| Meng, QY | 1 |
| Cui, FZ | 1 |
| Xu, YX | 1 |
| Dobsíková, R | 1 |
| Velísek, J | 1 |
| Wlasow, T | 1 |
| Gomulka, P | 1 |
| Svobodová, Z | 1 |
| Novotný, L | 1 |
| Mei, L | 1 |
| Song, CX | 1 |
| Jin, X | 1 |
| Che, YZ | 1 |
| Jin, Z | 1 |
| Sun, HF | 1 |
| Liang, L | 1 |
| Chen, Y | 1 |
| Xiong, S | 1 |
| Zeng, Z | 1 |
| Sun, M | 1 |
| Zhang, H | 1 |
| Lincoff, AM | 1 |
| Furst, JG | 1 |
| Ellis, SG | 1 |
| Tuch, RJ | 1 |
| Topol, EJ | 1 |
| Valéro, F | 1 |
| Hamon, M | 1 |
| Fournier, C | 1 |
| Meurice, T | 1 |
| Flautre, B | 1 |
| Van Belle, E | 1 |
| Lablanche, JM | 1 |
| Gosselin, B | 1 |
| Bauters, C | 1 |
| Bertrand, M | 1 |
| Kaul, S | 1 |
| Cercek, B | 1 |
| Rengstrom, J | 1 |
| Xu, XP | 1 |
| Molloy, MD | 1 |
| Dimayuga, P | 1 |
| Parikh, AK | 1 |
| Fishbein, MC | 1 |
| Nilsson, J | 1 |
| Rajavashisth, TB | 1 |
| Shah, PK | 1 |
| Edelman, ER | 1 |
| Nathan, A | 1 |
| Katada, M | 1 |
| Gates, J | 1 |
| Karnovsky, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized Trial of 3 Rapamycin-Eluting Stents With Different Polymer Coating Strategies For The Reduction of Coronary Restenosis (ISAR-TEST-3)[NCT00350454] | Phase 4 | 605 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lactic acid and Hyperplasia
| Article | Year |
|---|---|
Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
Topics: Aged; Anticoagulants; Catheterization; Cineangiography; Coated Materials, Biocompatible; Comorbidity | 2004 |
23 other studies available for lactic acid and Hyperplasia
| Article | Year |
|---|---|
Caffeic Acid-Grafted PLGA as a Novel Material for the Design of Fluvastatin-Eluting Nanoparticles for the Prevention of Neointimal Hyperplasia.
Topics: Drug Carriers; Endothelial Cells; Fluvastatin; Humans; Hyperplasia; Lactic Acid; Nanoparticles; Poly | 2022 |
Design and characterization of a perivascular PLGA coated PET mesh sustaining the release of atorvastatin for the prevention of intimal hyperplasia.
Topics: Atorvastatin; Caproates; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Liberation; Ex | 2018 |
Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.
Topics: Administration, Inhalation; Airway Remodeling; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Age | 2014 |
The role of Iex-1 in the pathogenesis of venous neointimal hyperplasia associated with hemodialysis arteriovenous fistula.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Arteriovenous Shunt, Surgical; Calcitriol; Chemok | 2014 |
Promoting endothelial recovery and reducing neointimal hyperplasia using sequential-like release of acetylsalicylic acid and paclitaxel-loaded biodegradable stents.
Topics: Absorbable Implants; Animals; Aorta, Abdominal; Aspirin; Biocompatible Materials; Calcium-Binding Pr | 2014 |
Inhibition of intimal hyperplasia of the vein graft with degradable poly lactic-co-glycolic acid vascular external sheaths carrying slow-release bosentan.
Topics: Animals; Blood Vessel Prosthesis; Bosentan; Delayed-Action Preparations; Endothelin Receptor Antagon | 2015 |
Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury.
Topics: Angioplasty, Balloon; Animals; Aorta; Cardiovascular Agents; Carotid Artery Diseases; Cell Movement; | 2017 |
Perivascular sustained release of atorvastatin from a hydrogel-microparticle delivery system decreases intimal hyperplasia.
Topics: Animals; Atorvastatin; Carotid Arteries; Delayed-Action Preparations; Drug Delivery Systems; Drug Li | 2016 |
Perivascular administration: The outside-in concept.
Topics: Animals; Atorvastatin; Delayed-Action Preparations; Drug Administration Routes; Gels; Humans; Hydrox | 2016 |
Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis.
Topics: Animals; Carotid Arteries; Cells, Cultured; Chemokine CCL2; DNA; Drug Delivery Systems; Genetic Ther | 2008 |
Sustained local drug delivery from a novel polymeric ring to inhibit intimal hyperplasia.
Topics: Absorbable Implants; Animals; Biocompatible Materials; Blood Vessels; Compressive Strength; Cyclospo | 2010 |
[Controlled release of siRNA nanoparticles loaded in a novel external stent prepared by emulsion electrospinning attenuates neointima hyperplasia in vein grafts].
Topics: Animals; Chitosan; Female; Graft Occlusion, Vascular; Hyperplasia; Lactic Acid; Male; Materials Test | 2009 |
Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts.
Topics: Animals; Blotting, Western; Cardiovascular Agents; Carotid Arteries; Carrier Proteins; Cell Prolifer | 2011 |
Enhanced efficacy of sirolimus-eluting bioabsorbable magnesium alloy stents in the prevention of restenosis.
Topics: Alloys; Angioplasty; Animals; Aorta, Abdominal; Aortic Diseases; Arterial Occlusive Diseases; Cardio | 2011 |
Locally infused gene containg nanoparticles to inhibit rabbit intimal hyperplasia.
Topics: Angioplasty, Balloon; Animals; Carotid Arteries; Carotid Artery Injuries; Chemokine CCL2; Disease Mo | 2011 |
Study of biodegradable and self-expandable PLLA helical biliary stent in vivo and in vitro.
Topics: Absorbable Implants; Animals; Bile Acids and Salts; Bile Ducts; Biocompatible Materials; Biodegradat | 2006 |
Effects of cypermethrin on some haematological, biochemical and histopathological parameters of common carp (Cyprinus carpio L.).
Topics: Alkaline Phosphatase; Animals; Blood Cell Count; Blood Cells; Butyrylcholinesterase; Carps; Creatine | 2006 |
[Surface-modified paclitaxel-loaded nanoparticles as local delivery system for the prevention of vessel restenosis].
Topics: Animals; Antineoplastic Agents, Phytogenic; Carotid Artery Injuries; Catheterization; Delayed-Action | 2007 |
[The inhibitive effect produced by local perfusion of tanshinone IIA nanoparticle on neointimal hyperplasia of rabbit carotid artery following intimal denudation].
Topics: Abietanes; Angioplasty, Balloon; Animals; Caprolactam; Carotid Arteries; Drug Carriers; Hyperplasia; | 2007 |
Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model.
Topics: Animals; Biocompatible Materials; Constriction, Pathologic; Coronary Disease; Coronary Vessels; Dexa | 1997 |
Intramural injection of biodegradable microspheres as a local drug-delivery system to inhibit neointimal thickening in a rabbit model of balloon angioplasty.
Topics: Angioplasty, Balloon; Animals; Anti-Inflammatory Agents; Biocompatible Materials; Coronary Disease; | 1998 |
Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB.
Topics: Angioplasty, Balloon; Animals; Arteries; Bleeding Time; Cell Division; Cyclic GMP; Drug Delivery Sys | 2000 |
Perivascular graft heparin delivery using biodegradable polymer wraps.
Topics: Angioplasty, Balloon; Animals; Anticoagulants; Biocompatible Materials; Biodegradation, Environmenta | 2000 |